remain posit rais po per share
forward think skill execut result rmd accomplish date
remain posit compani continu implement increment
posit sustain long term growth play activ role creat market
petit reimburs expans fund research support treat
obstruct sleep apnea rais po per share follow reason
multipl factor lift mask growth rate
addit increas patient base time rmd mask launch
competitor chart influenc growth rate chart expect rmd recent
mask growth momentum continu remaind also believ
rmd return long term growth rate moder prior cycl
basi frequent refresh mask portfolio ii lack meaning
competit also expect higher adher rate upsid resuppli
support lift long term growth rate
steadi predict devic demand
devic upgrad cycl longer key driver growth underli structur
devic revenu growth chang tend stabl year year
improv devic technolog come form softwar upgrad lift
growth rate previous factor steadi demand base
histor run rate chart
bofaml ahead consensu
npat estim ahead consensu valuat impli
forward price-to-earnings
full definit iqmethod sm measur see page
employ non-u affili bofa registered/qualifi research analyst
finra rule
refer import disclosur inform certain bofa merril lynch entiti take
respons inform herein particular jurisdict
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt naa
outsid equiti interest npat
chang work capit
 flow item int tax
 flow oper
oper
acquisit dispos invest
 flow invest
invest
 flow financ
financ
return capit employ
return equiti
iqmethod sm qualiti earn
full definit iqmethod sm measur see page
lead develop
manufactur medic devic mask cloud-
base softwar applic diagnos treat
manag respiratori disord headquart
san diego california focuss
connect health deliv better outcom
sleep apnea chronic obstruct pulmonari
outpac industri growth
market share place
everi market oper benefit
clinic data-captur proprietari
softwar boost therapi complianc
rate increas mask accessori growth
addit market develop
market activ target
moder sever osa suffer world-wide
price book valu
multipl factor lift mask growth rate
rmd new mask launch competitor significantli influenc revenu
growth amend mask revenu growth profil chart reflect
time new mask launch chart expect rmd recent mask growth
momentum continu remaind also believ rmd return
long term growth rate moder prior cycl compani
abl maintain low doubl digit growth refresh mask portfolio
frequent eg releas within twelv month
earlier year fph launch vitera full face mask australia canada
europ first mask releas sinc brevida subsequ
approv releas us despit vitera revenu europ fph
half year result sep overal mask revenu declin cc fph need
acceler seri mask lift market order take market
three mask launch last four year philip respiron phia
current pose signific threat new mask custom octob phia
report growth deceler due inabl respond quickli tariff
howev given histor steadi profil mark launch anticip phia
may mask pipelin come market near futur
chart mask revenu profil adjust reflect mask cycl
chart recent mask launch fuel growth
mask launch key competitor
fph announc releas anoth mask full seri follow
fph disclos osa growth rate half yearli basi purpos analysi
estim growth rate full year
long term growth rate lift
underli mask revenu growth driven increas core osa patient
base global support increas awar diagnosi condit
ii improv adher rate less churn ii resuppli support increas
mask utilis number mask use per patient per annum take
factor consider forecast higher adher rate upsid
resuppli growth post run higher histor growth rate
myair airview increas adher
level complianc high drop-out cpap patient histor
constrain growth success utilis technolog solut rais
complianc level program airview myair app myair
patient help patient monitor sleep access support materi myair
airview shown materi increas level adher adher
day vs expect takeup myair continu grow
especi new osa patient reduc dropout level grow number
activ mask-purchas patient estim adher rate
reach addit ppt growth achiev purpos
valuat assum grow five year
exhibit year ago mask util
mask util number mask per patient per annum
exhibit today increas potenti increas
grow patient base support resuppli connect
us insur reimburs four mask per year averag mask utilis sit
well mask patient seek minimis co-pay ii due
complex identifi user demand brightre resuppli modul address
latter whilst disclos proport mask growth attribut
resuppli channel check indic resuppli support utilis
increas resm conduct studi de-identifi data
show use airview brightre increas level complianc adher
year vs believ mask utilis continu upward
trajectori toward dme use resuppli algorithm becom
sophist mask utilis reach addit growth
achiev purpos valuat assum grow five
patient engag use new technolog improv adher posit airway pressur
patient engag use new technolog improv adher posit airway pressur
therapi malhotra et al chest studi support adher improv effect
telemedicin educ telemonitor continu posit airway pressur adher tele-
osa random trial hwang et al propensity-adjust compar analysi pap
adher associ use myair crocker et al
upgrad cycl longer key driver
cpap devic sale histor subject five year upgrad cycl new
devic launch unlik growth devic revenu follow
launch first market connect
capabl repeat without anoth signific step innov
underli structur devic revenu growth chang tend
stabl year year improv devic technolog come form softwar
upgrad advantag consist industri
leader incorpor new technolog osa treatment given would
expect achiev market devic growth expect
increment posit devic growth
increas devic growth rate us previous align
recent trend post launch connect care
chart devic growth volatil moder post connect
activ work expand reimburs new geographi sinc
benefit expand reimburs program includ
cloud-connected/telemonitor devic japan franc south korea expect
countri western europ follow franc footstep includ
germani uk open market repres upsid
reimburs support larg number clinic trial show efficaci
cpap treatment osa suffer substanti grow bodi clinic
research show risk untreat osa link cardiovascular
complic stroke even efficaci cpap treatment
shahar whitney cw redlin et al sleep-disord breath cardiovascular diseas cross-
section result sleep heart studi american journal respiratori critic care
sullivan ce issa fg berthon-jon eve revers obstruct sleep apnoea continu
posit airway pressur appli nare lancet
buchner nj sanner bm borgel rump lc continu posit airway pressur treatment mild
moder obstruct sleep apnea reduc cardiovascular risk respir crit
gallardo fernandez-palacin mortal obstruct sleep ap- neahypopnea patient treat
posit airway pressur chest
devic growth support chang competit landscap
move two-play market fph shift focu osa mask hospit care
ventil segment ii impact tariff phia saw growth deceler
due sluggish respons shift manufactur suppli chain
likelihood spillov repres posit
marin jm carrizo sj vicent agusti ag long- term cardiovascular outcom men
obstruct sleep apnoeahypopnoea without treatment continu pos- itiv airway
pressur observ studi lancet
avlonit kapsimali varouchaki vardava ci behraki adher cpap therapi
improv qualiti life reduc symptom among obstruct sleep apnea syndrom patient sleep
gile tl lasserson tj smith bh white wright cate cj continu posit airway pressur
obstruct sleep apnoea adult cochran databas systemat review
chart roe
price object per share base dcf
valuat dcf use wacc termin growth rate beta
downsid risk po loss momentum saa busi market
educ effort achiev expect revenu growth reimburs
chang health ministri phi poor recept new product launch
technolog advanc competitor product fx chang
lyann harrison herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
